The prospective study by Parmar and coauthors is in-
teresting in that it showed little evidence of IFIS in 29 patients on
1. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated
systemic a-blockers, including 3 on tamsulosin. This is consistent
with tamsulosin. J Cataract Refract Surg 2005; 31:664–673
with the retrospective study reported in our paper, in which IFIS
2. Schwartz G. A rational ordering of the actions of antipsychotic drugs.
was not recorded in 11 patients taking systemic prazosin, terazo-
sin, or doxazosin and was not always noted in patients on tamsu-losin. However, we are aware of several anecdotal reports of IFISoccurring in patients on terazosin and doxazosin.
The finding that an antipsychotic medication with
Many factors could variably affect the ability of a systemic a-
strong a-antagonist properties may have caused IFIS is most in-
antagonist to cause IFIS. These would include the dosing and du-
teresting. Now that this syndrome of IFIS has been defined, it
ration of treatment, the intraocular drug level achieved, and the
will be interesting to see to what extent a-antagonists besides
relative affinity of the drug for the iris dilator muscle receptors.
tamsulosin are associated with this syndrome. The technique of
We previously noted that tamsulosin appears to have a stronger
direct intracameral injection of phenylephrine certainly deserves
affinity for the a-1A receptor than other a-antagonists. This could
affect both the duration and constancy of receptor blockade.
dDavid F. Chang, MD, John R. Campbell, MD
Finally, there are likely to be individual differences in one’s
susceptibility to developing IFIS. We believe that the association
of IFIS and systemic a-blockers will prove to represent a con-tinuum of frequency and severity, depending on the drug andindividual susceptibility. We agree that larger prospective studies
Alpha blockers (also known as a-adrenergic blockers or a-adren-
will be necessary to better quantify the risk for IFIS.dDavid F.
ergic antagonists) are used primarily in the treatment of systemic
hypertension and benign prostatic hyperplasia. They block the ef-fects of stress hormones that lead to an increase in heart rate andblood pressure. Alpha receptor blockade in hyperplastic prostatictissue, prostatic capsule, and bladder neck decreases smooth mus-
cle tone, thereby decreasing resistance to urinary flow and im-proving symptoms.
Concern about the use of these medications, especially tamsu-
We thank Gu¨ell et for introducing this unprecedented phaco-
losin (Flomax), has been linked to causing the intraoperative floppy
emulsification technique. The key to success is the free and unre-
iris syndrome (IFIS).We wondered whether all a-antagonists
stricted rotatory movement of the nucleus. With this technical
might be a cause of intraoperative difficulties. To assess the risk
prerequisite, this variant of phacoemulsification does not appear
in a typical unselected population having phacoemulsification cat-
to be as surgically simple and safe as other techniques. The feasi-
aract surgery, we prospectively investigated 100 consecutive pa-
bility of this technique would be undermined by some cataract
tients to assess the prevalence of the use of a-antagonists and the
possible relationship to perioperative problems.
First, what would be the surgical strategy in conditions such
Our results showed that 29 patients (29%) were on
as zonular dehiscence or dense posterior subcapsular cataract in
a-antagonists: doxazosin, 11 patients; indoramin, 8; prazosin, 5;
which rotating the lens is difficult? Second, the usual position of
terazosin, 2; tamsulosin, 3; no patient was taking alfuzosin. Of
the phaco tip during rotatory movement is at the capsulorhexis
these patients, 68% were women. No patient had bilateral surgery.
Theoretically, this has the advantage of curtailing the risk
The patients on a-antagonists had been on the medication for at
for endothelial and posterior capsule injury. However, the close
proximity of the edge of the capsulorhexis to the phaco tip may
Only 1 patient had a perioperative problem
increase the risk for anterior capsule damage during phacoemul-
pupil. No patient had IFIS. None of the 3 patients on Flomax
sification. If undetected, an anterior capsule tear may extend
across the equator, leading to a dropped nucleus or, later, to IOL
Patients who have cataract surgery are typically elderly and
decentration.This is an important safety issue that should not
will usually be on some form of medication. It is important to ap-
be overlooked while performing the phaco rolling technique.
preciate that these can cause interactions that may affect the sur-
The authors did not report any anterior capsule injury, and we
gery. However, while a-antagonists are widely prescribed in the
are interested to learn the precautions for reducing or preventing
population having cataract surgery, our pilot study did not show
a significant link between these drugs and perioperative problems. In particular, taking Flomax does not always result in IFIS. The
1. Gu¨ell JL, Vazquez M, Lucena J, et al. Phaco rolling technique. J Cataract
1. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated
2. Davison JA. Analysis of capsular bag defects and intraocular lens posi-
with tamsulosin. J Cataract Refract Surg 2005; 31:664–673
tions for consistent centration. J Cataract Refract Surg 1986; 12:24–129
J CATARACT REFRACT SURG - VOL 31, DECEMBER 2005
Beknopte handleiding ‘Zorg voor dwarslaesiepatiënten’ Bij dwarslaesiepatiënten kunnen zich specifieke problemen voordoen, zoals stoornissen in vasomotoriek, sensibiliteit, blaas-/darmfunctie en seksualiteit. Speciaal voor de huisarts daarom een beknopt overzicht van aandachtspunten in de zorg voor dwarslaesiepatiënten in de chronische fase. Urineweginfecties (UWI) De symptomen v
Richard E. Kast*,1 and Daniele Focosi † ,1*Department of Psychiatry, University of Vermont,Burlington, VT 05401, USA; †Division of Hematology,University of Pisa, 56126 Pisa, ItalyTreating Chronic MyelogenousLeukemia and Glioblastomawith ImatinibChronic myelogenous leukemia (CML) can be controlled for years with the tyrosine kinase inhibitor imatinib but be-cause imatinib poorly penetrates